香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 中國北京，2025年8月29日 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由北京市春立 正達醫療器械股份有限公司（「本公司」）作出。 茲載列本公司在上海證券交易所網站刊登之《北京市春立正達醫療器械股份有 限公司關於計提2025 年半年度資產減值準備的公告》，僅供參閱。 承董事會命 北京市春立正達醫療器械股份有限公司 董事長 史文玲 截至本公告日期，本公司執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生； 本公司非執行董事為王鑫先生；及本公司獨立非執行董事為徐泓女士、翁杰先生及黃德盛先生 ...

Core Viewpoint - Spring Medical reported strong financial performance for the first half of 2025, with significant year-on-year growth in revenue and net profit, indicating a positive trend in the company's operations and market position [1]. Financial Performance - The company's revenue for the first half of 2025 was 488 million yuan, representing a year-on-year increase of 28.27% [1]. - The net profit attributable to shareholders was 114 million yuan, up 44.85% year-on-year [1]. - The basic earnings per share were 0.30 yuan, with a weighted average return on equity of 3.98% [1]. - The gross margin for the first half of 2025 was 67.09%, a decrease of 4.43 percentage points year-on-year, while the net margin was 23.48%, an increase of 2.71 percentage points [1]. Cost Structure - Total operating expenses for the first half of 2025 were 169 million yuan, a decrease of 22.66 million yuan compared to the same period last year [2]. - The expense ratio was 34.61%, down 15.75 percentage points year-on-year [2]. - Sales expenses decreased by 13.65%, while management expenses increased by 33.24% [2]. Shareholder Information - As of the end of the first half of 2025, the total number of shareholders was 5,920, a decrease of 1,262 from the previous quarter, representing a decline of 17.57% [2]. - The average market value per shareholder increased from 724,200 yuan at the end of the previous quarter to 1,204,500 yuan, an increase of 66.32% [2]. Company Overview - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, specializes in the research, production, and sales of implantable orthopedic medical devices [3]. - The company's main products include joint prosthetics and spinal implants, with a revenue composition of 99.92% from medical devices [3]. - The company operates in the medical device sector, specifically in the sub-sector of medical consumables [3].

证券代码：688236 证券简称：春立医疗 公告编号：2025-036 北京市春立正达医疗器械股份有限公司 第五届监事会第十八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 北京市春立正达医疗器械股份有限公司（以下简称"公司"）第五届监事会 第十八次会议于 2025 年 8 月 29 日以现场加通讯方式召开。本次会议由公司监事 会主席张杰先生召集并主持，本次会议应参加监事 3 名，实际参加监事 3 名， 本次会议的召集和召开程序符合《中华人民共和国公司法》及《公司章程》的有 关规定，会议决议合法、有效。 二、监事会会议审议情况 经与会监事审议，以记名投票的方式一致通过以下议案： （一）审议通过《关于公司 2025 年半年度报告及其摘要的议案》 具体内容详见公司披露于上海证券交易所网站（www.sse.com.cn）的《2025 年半年度报告》及《2025 年半年度报告摘要》。 （二）审议通过《关于公司 2025 年半年度募集资金存放与实际使用情况的 专项报告的议案》 表决结果：3 ...

证券代码：688236 证券简称：春立医疗 公告编号：2025-035 北京市春立正达医疗器械股份有限公司 第五届董事会第二十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 董事会会议召开情况 北京市春立正达医疗器械股份有限公司（以下简称"公司"）第五届董事会第 二十六次会议于 2025 年 8 月 29 日以现场加通讯方式召开。本次会议通知已于 2025 年 8 月 15 日发出。本次会议由公司董事长史文玲女士召集并主持，会议应出席董 事 8 名，实际出席董事 8 名。本次会议的召集、召开和表决程序符合《中华人民 共和国公司法》等法律、行政法规、部门规章、规范性文件和《公司章程》的相 关规定，会议决议合法、有效。 二、董事会会议审议情况 经与会董事审议，以记名投票的方式一致通过以下议案： （一）审议通过《关于公司 2025 年半年度报告及其摘要的议案》 公司 2025 年半年度报告的编制和审核程序符合法律、法规及《公司章程》、 公司内部管理制度的各项规定，公允地反映了公司 2025 年半年度的财务 ...

华泰联合证券有限责任公司（以下简称"华泰联合证券"）作为北京市春立 正达医疗器械股份有限公司（以下简称"春立医疗"或"公司"）首次公开发行 股票并在科创板上市持续督导阶段的保荐机构，根据《证券发行上市保荐业务管 理办法》、《上市公司募集资金监管规则》、《上海证券交易所科创板股票上市规 则》、《上海证券交易所科创板上市公司自律监管指引第 1 号—规范运作》等有关 规定，对春立医疗拟使用部分闲置募集资金进行现金管理的事项进行了审慎核 查，核查情况及核查意见如下： 一、募集资金的基本情况 经上海证券交易所科创板股票上市委员会审核同意，并根据中国证券监督管 理委员会出具证监许可〔2021〕3702 号文核准，公司获准向社会公众公开发行 人民币普通股（A 股）股票 38,428,000 股，每股面值人民币 1.00 元，发行价格 为每股人民币 29.81 元，共计募集资金人民币 114,553.87 万元。扣除发行费用（不 含增值税）后，募集资金净额为 106,712.83 万元。上述募集资金到位情况经大信 会计师事务所（特殊普通合伙）审验，并由其出具《验资报告》（大信验字[2021] 第 3-00041 号）。 公司 ...

格隆汇8月29日丨春立医疗(688236.SH)公布半年度报告，营业收入4.88亿元，同比增长28.27%，归属于 上市公司股东的净利润1.14亿元，同比增长44.85%，归属于上市公司股东的扣除非经常性损益的净利润 1.06亿元，同比增长61.09%。 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2025, representing a 15% year-over-year growth[4]. - The company's operating revenue for the first half of 2025 reached ¥487,596,405.66, representing a 28.27% increase compared to ¥380,130,570.92 in the same period last year[22]. - Total profit for the reporting period was ¥127,312,520.25, a year-on-year growth of 53.26% from ¥83,069,962.55[24]. - Net profit attributable to shareholders was ¥114,469,490.87, up 44.85% from ¥79,026,078.82 in the previous year[24]. - The net cash flow from operating activities was ¥141,486,383.10, a significant recovery from a negative cash flow of -¥69,057,888.52 in the same period last year[22]. - Basic earnings per share increased to ¥0.30, reflecting a 42.86% rise from ¥0.21 in the same period last year[23]. - The weighted average return on net assets rose to 3.98%, an increase of 1.27 percentage points compared to 2.71% in the previous year[23]. - The company reported a net profit of 2,353,071.29 RMB from Hebei Chunli Hangnuo New Material Technology Co., with an operating income of 32,263,678.81 RMB, representing a significant contribution to the overall performance[111]. - The company reported a total comprehensive income of 78,422,797, reflecting a significant increase compared to the previous period[190]. Market Expansion and Strategy - The company has outlined a positive outlook for the second half of 2025, projecting a revenue growth of 10% to 1.32 billion RMB[4]. - The company is expanding its market presence, targeting new regions in Southeast Asia, with an estimated investment of 100 million RMB for market entry[4]. - A strategic acquisition of a smaller competitor is in progress, which is anticipated to enhance the company's product portfolio and increase market share by 5%[4]. - The company is actively expanding its international market presence while solidifying its domestic market leadership[31]. - The company aims to expand its market presence through innovative product development and strategic partnerships in the orthopedic sector[68]. Research and Development - The company has been expanding its international market presence, contributing to the growth in export business[24]. - Research and development expenditure accounted for 10.43% of operating revenue, a decrease of 7.37 percentage points from 17.80% in the same period last year[23]. - The total R&D investment for the period was approximately ¥50.85 million, a decrease of 24.84% compared to ¥67.66 million in the same period last year, with R&D investment accounting for 10.43% of operating revenue, down 7.37 percentage points[89]. - The company has developed advanced technologies for shoulder joint prosthetics, enhancing the anti-rotation performance and extending the lifespan of implants[72]. - The company is committed to advancing its R&D capabilities to maintain a competitive edge in the orthopedic medical device market[68]. Product Development and Innovation - New product development includes the launch of a cutting-edge medical device expected to generate an additional 200 million RMB in revenue by the end of 2025[4]. - The company has developed several first-in-market products, including the BIOLOX® delta ceramic joint prosthesis, which is the most widely used generation in China[31]. - The company has developed a range of knee joint prosthetics, including initial fixation and revision types, to cater to diverse surgical needs[41]. - The company has developed multiple core technologies in orthopedic medical devices, including hip joint, knee joint, and spinal core technologies, enhancing product performance and reliability[68]. - The company has introduced a customized bone defect repair technology that utilizes advanced digital processing to meet the unique needs of patients[74]. Financial Management and Governance - The financial report has been confirmed as accurate and complete by the company's management team, ensuring transparency for investors[4]. - The board has approved a profit distribution plan, with no plans for capital increase through reserves for this reporting period[4]. - The company has not disclosed any stock incentive plans or employee stock ownership plans, suggesting a potential area for future development[118]. - The company has appointed Lu Hongyue as the new Chief Financial Officer, following the resignation of Li Yumei, which is expected to ensure smooth financial management[114]. - The company has established a rigorous quality management system compliant with international standards, ensuring product reliability and stability in the competitive market[66]. Risk Management - The company has identified potential risks, including regulatory changes that could impact operations, and has developed mitigation strategies[4]. - The company is facing risks related to product registration and approval processes, which are lengthy and costly, potentially impacting future growth[99]. - The company is closely monitoring national procurement policies that may affect product pricing and gross margins, aiming to enhance product innovation and market share[100]. Shareholder and Equity Information - The total amount of raised funds reached CNY 1,145,538,680, with a net amount of CNY 1,067,128,292.23, representing a utilization rate of 47.32% as of the reporting period[138]. - The controlling shareholders, Shi Chunbao and Yue Shujun, committed to not transferring or entrusting the management of their shares for 36 months post-listing[123]. - The company has not engaged in any major asset or equity sales during the reporting period, maintaining its current structure[111]. - The total equity attributable to shareholders rose to CNY 2,907,655,225.72 from CNY 2,819,902,283.28, reflecting an increase of about 3.11%[160]. - The company has a total of CNY 1,304,179,665.00 in other comprehensive income, contributing to the overall financial health[184].

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 截至发稿，春立医疗市值为86亿元。 每经头条（nbdtoutiao）——近120个品牌、1600辆车逐鹿西南！下半年国内首个A级车展开幕：新能 源"第三极"将改写车市格局 （记者 王可然） 每经AI快讯，春立医疗（SH 688236，收盘价：22.35元）8月29日晚间发布半年度业绩报告称，2025年 上半年营业收入约4.88亿元，同比增加28.27%；归属于上市公司股东的净利润约1.14亿元，同比增加 44.85%；基本每股收益0.3元，同比增加42.86%。 ...

证券代码：688236 证券简称：春立医疗 公告编号：2025-037 北京市春立正达医疗器械股份有限公司 2025 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会《上市公司募集资金监管规则》、《上海证券 交易所科创板上市公司自律监管指引第 1 号——规范运作》的相关规定，北京市 春立正达医疗器械股份有限公司（以下简称"本公司"或"公司"）董事会对 2025 年半年度募集资金存放与实际使用情况作如下报告： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经上海证券交易所科创板股票上市委员会审核同意，并根据中国证券监督管 理委员会出具证监许可〔2021〕3702 号同意注册的文件，公司获准向社会公众 公开发行人民币普通股（A 股）股票 38,428,000 股，每股面值人民币 1.00 元， 发行价格为每股人民币 29.81 元，共计募集资金人民币 114,553.87 万元。扣除发 行费用（不含增值税）后，募集资金净额为 106,712. ...

证券代码：688236 证券简称：春立医疗 公告编号：2025-038 北京市春立正达医疗器械股份有限公司 关于使用部分闲置募集资金和自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京市春立正达医疗器械股份有限公司（以下简称"公司"）于 2025 年 8 月 29 日分别召开了第五届董事会第二十六次会议、第五届监事会第十八次会议，会议审议 通过了《关于使用部分闲置募集资金和自有资金进行现金管理的议案》，同意公司在 不影响公司募集资金投资项目（以下简称"募投项目"）正常实施并保证募集资金安 全的前提下，使用最高不超过 7 亿元（含 7 亿元）的部分闲置募集资金及最高不超过 14 亿元（含 14 亿元）的自有资金进行现金管理。在上述额度内，资金可以滚动使用， 使用期限自董事会审议通过之日起 12 个月内有效。 具体情况如下： 单位：人民币元 董事会授权公司管理层在授权额度和期限内行使现金管理投资决策权并签署相关 合同文件。上述事项在公司董事会审批权限范围内，无需提交公司股东会审批。公司 监事会发表 ...